Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | FNTA | P49354 | 6/20 | 0.55 |
| ▸ | FNTB | P49356 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526077 | 1.00 | KDM4E (1.00) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL358253 | 1.00 | KDM4E (1.00) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL310619 | 1.00 | KDM4E (1.00) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL10566443 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL9366045 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL1470207 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A | |
| Geranylgeranoic Acid SCHEMBL10781543 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL7943006 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A | |
| SCHEMBL7943004 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A | |
| Geranylgeranoic Acid SCHEMBL10405196 | 0.96 | KDM4E (0.92) | KDM4EATMPOLBKDM1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163333-A1 | METHODS AND SYSTEMS FOR DISPERSING CATALYST PRECURSORS INTO HYDROCARBON FEEDSTOCKS TO FORM CONDITIONED FEEDSTOCKS CONTAINNG NONPETROLEUM-DERIVED HYDROCARBONS | HYDROCARBON TECHNOLOGY & INNOVATION, LLC | 2025-05-22 | — | — | US | claimed |
| WO-2025106443-A1 | METHODS AND SYSTEMS FOR DISPERSING CATALYST PRECURSORS INTO HYDROCARBON FEEDSTOCKS TO FORM CONDITIONED FEEDSTOCKS CONTAINING NONPETROLEUM-DERIVED HYDROCARBONS | HYDROCARBON TECHNOLOGY & INNOVATION, LLC (US) | 2025-05-22 | — | — | WO | claimed |
| US-12275896-B2 | Catalytic hydrotreating of feedstocks | NESTE OYJ (FI) | 2025-04-15 | — | — | US | claimed |
| CN-117838801-A | Orchid composite extract and its use in preparing composition with anti-depression effect | 福建农林大学 | 2024-04-09 | — | — | CN | claimed |
| EP-4219663-A2 | A PROCESS FOR MANUFACTURING CATALYTIC MICROPARTICLES | Neste Oyj (FI) | 2023-08-02 | — | — | EP | claimed |
| CN-115777797-A | Processing method of Zijuan white tea for green removing process | 广西南亚热带农业科学研究所 | 2023-03-14 | — | — | CN | claimed |
| US-20230069301-A1 | CATALYTIC HYDROTREATING OF FEEDSTOCKS | NESTE OYJ (FI) | 2023-03-02 | — | — | US | claimed |
| EP-4081623-A1 | CATALYTIC HYDROTREATING OF FEEDSTOCKS | Neste Oyj (FI) | 2022-11-02 | — | — | EP | claimed |
| CN-110621654-B | TRPV1 modulator compounds | 安塔尔遗传学公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114846121-A | Catalytic hydrotreating of feedstock | 耐思特公司 | 2022-08-02 | — | — | CN | claimed |
| WO-2012113891-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2012-08-30 | — | — | WO | claimed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | claimed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | claimed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | claimed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| CN-1096292-C | Method for preparing bimetallic ruthenium/tin catalyst | PHODIA CHIMIE (FR) | 2002-12-18 | — | — | CN | claimed |
| US-4115417-A | ENANTIOSELECTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1978-09-19 | — | — | US | claimed |
| US-3971827-A | Manufacture of poly-(cis)-isoprenols | G. D. SEARLE & CO. (US) | 1976-07-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | APP, PARK7, BACE1 | KDM4E 4222/4885ATM 2268/4885POLB 3819/4885 |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | APP, BACE1, PSEN1 | KDM4E 3471/4885ATM 2458/4885POLB 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.